Bringing the fundamentals into focus…
Back to Keros Therapeutics, Inc.
How Keros Therapeutics, Inc. stacks up
KROS · against 252 other Healthcare companies of similar size
Valuation
33/ 100
Below the middle of the pack.
Ranked #124 of 253 · scores higher than 41% of peers
Bars: peers in each 10-point band of the valuation score45 peers with a valuation score of 30–39, including KROS · Click a bar to see the companies
Why valuation scores 33?
Weighted metrics compared with all Healthcare companies.Mainly because of its earnings yield and free cash flow yield, which are weaker than most Healthcare peers.
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Earnings yield: -38.7% vs peer median 1.5%
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Free cash flow yield: -22.6% vs peer median 0.0%
- Cash exceeds market value plus debt, so EBITDA yield is not meaningful and is left out.
Metric by metric
Position: dot = KROS, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | KROS | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 236 reported | -29.7% | -1.3% | 22% | 30% | |
| EBITDA yieldHigher is better · 259 reported | 934.6% | 1.4% | 100% | 50% | |
| Free cash flow yieldHigher is better · 145 reported | -22.6% | -12.4% | 34% | 20% | |
| Book yieldHigher is better · 241 reported | 122.2% | 61.5% | 80% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around KROS| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 1.1B HKD (≈$146M) | 99 | 72 | |
| 1 | 1.4B HKD (≈$181M) | 99 | 61 | |
| 1 | 2.9B HKD (≈$365M) | 99 | 84 | |
| 1 | 3.1B HKD (≈$396M) | 99 | 61 | |
| 1 | 29.0B JPY (≈$197M) | 99 | 56 | |
| 124 | 216M USD | 33 | 44 | |
| 124 | 126M USD | 33 | 32 | |
| 124 | 285M USD | 33 | 38 | |
| 124 | 338M USD | 33 | ||
| 124 | 215M USD | 33 | 34 | |
| 124 | 239M USD | 33 | 38 | |
| 124 | 110M USD | 33 | 54 | |
| 124 | 117M USD | 33 | 40 | |
| 124 | 276M USD | 33 | 46 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score